The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

London pre-open: Stocks still lacking direction

Tue, 20th Dec 2011 07:16

After yesterday's aimless trading session, London's blue-chips are seeking direction again today, with City traders tipping the FTSE 100 will open down 14 points from yesterday's close of 5,365. Pharmaceuticals giant AstraZeneca said full year core earnings per share (EPS) are set to be in the lower half of its guidance range as a result of impairment charges taken following setbacks in two of its drug development programmes: Olaparib and TC-5214.Bus and train group National Express remains firmly on track to deliver revenue and profit growth in 2011 in every one of its divisions. Trading across the group remains strong, the company said, and full year profit is expected to be in line with the board's previous expectations.Advertising titan WPP, led by Sir Martin Sorrell, has acquired a 49% stake in Chinese peer Nanjing Yindu Advertising and Commerco Co for an undisclosed sum.--jh

Related Shares

More News
Today 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was ...

Today 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announ...

3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsort...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.